UMMS Affiliation

Department of Pediatrics

Publication Date

2021-12-01

Document Type

Article

Disciplines

Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Immunology and Infectious Disease | Infectious Disease | Nutritional and Metabolic Diseases | Respiratory Tract Diseases | Virus Diseases

Abstract

The novel SARS-CoV-2 coronavirus (COVID-19) has become a global health crisis since its initial outbreak in Wuhan, China in December 2019. On January 30, 2020, the WHO recognized the COVID-19 outbreak as a Public Health Emergency, and on March 11, 2020, it was declared a pandemic. Although all age groups have been affected, patients with cystic fibrosis (CF) and patients with type 1 or type 2 diabetes have been categorized as highly vulnerable to SARS-CoV-2 infection. Thus far, studies have found that the incidence of SARS-CoV-2 in the CF population is lower than the general population. We review the underlying protective mechanisms which may reduce inflammation and lung damage in CF patients, thus decreasing their risk of severe COVID-19. While the effect of SARS-CoV-2 in those with diabetes related to CF is unknown, other forms of diabetes have been associated with more severe disease. To further understand the potential impact of SARS-CoV-2 in cystic fibrosis-related diabetes, we provide a comprehensive overview of the potential factors contributing to COVID-19 severity in other forms of diabetes, including direct viral effect on the pancreas and indirect effects related to hyperglycemia and immune dysregulation.

Keywords

ACE2, COVID-19, Cystic fibrosis, Cystic fibrosis-related diabetes, Diabetes, SARS-CoV-2

Rights and Permissions

© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

DOI of Published Version

10.1016/j.jcte.2021.100268

Source

Mason K, Hasan S, Darukhanavala A, Kutney K. COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes. J Clin Transl Endocrinol. 2021 Dec;26:100268. doi: 10.1016/j.jcte.2021.100268. Epub 2021 Oct 25. PMID: 34722160; PMCID: PMC8545686. Link to article on publisher's site

Journal/Book/Conference Title

Journal of clinical and translational endocrinology

Related Resources

Link to Article in PubMed

PubMed ID

34722160

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS